Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 6/20 | 0.47 |
| ▸ | DHODH | Q02127 | 8/20 | 0.44 |
| ▸ | EIF4A1 | P60842 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25118616 | 0.91 | DHODH (0.46) | CDK2DHODHEIF4A1 | |
| SCHEMBL23590233 | 0.90 | DHODH (0.51) | CDK2DHODH | |
| SCHEMBL23590118 | 0.89 | DHODH (0.55) | CDK2DHODHEIF4A1 | |
| SCHEMBL26074561 | 0.86 | EIF4A1 (0.45) | DHODHEIF4A1 | |
| SCHEMBL23590147 | 0.85 | DHODH (0.46) | CDK2DHODHEIF4A1 | |
| SCHEMBL23590057 | 0.85 | KDM4E (0.49) | CDK2DHODHEIF4A1RXRA | |
| SCHEMBL23590133 | 0.83 | DHODH (0.45) | CDK2DHODHEIF4A1 | |
| SCHEMBL23590117 | 0.83 | DHODH (0.53) | DHODHPTPN11 | |
| SCHEMBL26074181 | 0.83 | PLA2G2A (0.52) | CDK2DHODHRXRANR1H2NR1H3 | |
| SCHEMBL23590149 | 0.82 | DHODH (0.44) | CDK2DHODHEIF4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230109418-A1 | COMPOSITIONS FOR USE FOR THE INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | OHIO STATE INNOVATION FOUNDATION (US) | 2023-04-06 | — | — | US | disclosed |
| WO-2023278778-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD47-SIRPΑ THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2021134045-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021133831-A1 | COMPOSITIONS FOR USE FOR THE INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | OHIO STATE INNOVATION FOUNDATION (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | DHODH, CD38, DPYD | CDK2 3123/4885DHODH 1/4885EIF4A1 4791/4885 |
| US-20230109418-A1 | COMPOSITIONS FOR USE FOR THE INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | DHODH, DDO, DLD | CDK2 2174/4885DHODH 1/4885EIF4A1 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.